FOXO3a represses VEGF expression through FOXM1-dependent and -independent mechanisms in breast cancer.
about
The Role of Forkhead Box Protein M1 in Breast Cancer Progression and Resistance to TherapyRegulation of Bim in Health and DiseaseTrastuzumab-resistant cells rely on a HER2-PI3K-FoxO-survivin axis and are sensitive to PI3K inhibitorsTwist1 promotes gastric cancer cell proliferation through up-regulation of FoxM1.Inhibiting Histone Deacetylase as a Means to Reverse Resistance to Angiogenesis Inhibitors: Phase I Study of Abexinostat Plus Pazopanib in Advanced Solid Tumor Malignancies.FOXM1 recruits nuclear Aurora kinase A to participate in a positive feedback loop essential for the self-renewal of breast cancer stem cells.Effect of high-intensity exercise on aged mouse brain mitochondria, neurogenesis, and inflammation.FoxM1 influences embryo implantation and is regulated by 17 beta-estradiol and progesterone in mouse uteri and endometrium cells.Evaluating the evidence for targeting FOXO3a in breast cancer: a systematic review.Identification of FOXM1 as a therapeutic target in B-cell lineage acute lymphoblastic leukaemia.Paclitaxel targets FOXM1 to regulate KIF20A in mitotic catastrophe and breast cancer paclitaxel resistance.Reprogramming of Normal Fibroblasts into Cancer-Associated Fibroblasts by miRNAs-Mediated CCL2/VEGFA Signaling.High MicroRNA-370 Expression Correlates with Tumor Progression and Poor Prognosis in Breast CancerBRCA1 positively regulates FOXO3 expression by restricting FOXO3 gene methylation and epigenetic silencing through targeting EZH2 in breast cancerHuman endometrial mesenchymal stem cells exhibit intrinsic anti-tumor properties on human epithelial ovarian cancer cells.The Forkhead Box M1 protein regulates BRIP1 expression and DNA damage repair in epirubicin treatment.Bis(3,5-diiodo-2,4,6-trihydroxyphenyl)squaraine photodynamic therapy disrupts redox homeostasis and induce mitochondria-mediated apoptosis in human breast cancer cells.FOXM1 and its oncogenic signaling in pancreatic cancer pathogenesisNuclear FOXO3 predicts adverse clinical outcome and promotes tumor angiogenesis in neuroblastoma.Tumour promoting and suppressing roles of the atypical MAP kinase signalling pathway ERK3/4-MK5Role of the forkhead transcription factor FOXO-FOXM1 axis in cancer and drug resistance.FOX(M1) news--it is cancer.Role and regulation of the forkhead transcription factors FOXO3a and FOXM1 in carcinogenesis and drug resistance.Genetics of breast cancer bone metastasis: a sequential multistep pattern.Insights into a Critical Role of the FOXO3a-FOXM1 Axis in DNA Damage Response and Genotoxic Drug Resistance.Forkhead box K2 modulates epirubicin and paclitaxel sensitivity through FOXO3a in breast cancer.Oxidative Stress Gene Expression Profile Correlates with Cancer Patient Poor Prognosis: Identification of Crucial Pathways Might Select Novel Therapeutic Approaches.FOXM1 expression in rhabdomyosarcoma: a novel prognostic factor and therapeutic target.FOXM1: A novel drug target in gastroenteropancreatic neuroendocrine tumors.The DEAD box protein p68: a crucial regulator of AKT/FOXO3a signaling axis in oncogenesis.Activation of protein kinase CK2 attenuates FOXO3a functioning in a PML-dependent manner: implications in human prostate cancer.The Emerging Roles of Forkhead Box (FOX) Proteins in Osteosarcoma.FoxO1 and FoxM1 transcription factors have antagonistic functions in neonatal cardiomyocyte cell-cycle withdrawal and IGF1 gene regulation.Oncogenic regulation of tumor metabolic reprogramming.Knockdown of MALAT1 expression inhibits HUVEC proliferation by upregulation of miR-320a and downregulation of FOXM1 expression.FoxM1 promotes epithelial-mesenchymal transition of hepatocellular carcinoma by targeting Snai1.Forkhead box transcription factors in cancer initiation, progression and chemotherapeutic drug response.Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers.MiR-629 promotes human pancreatic cancer progression by targeting FOXO3.FOXOs in Cancer Immunity: Knowns and Unknowns.
P2860
Q26768290-F3F305A7-FB16-4CAE-AF41-203FEE7748C4Q26781203-90CC276A-D54E-4789-B560-4DC0CD3A4D41Q27851975-5341876F-ACC0-4795-82D0-1BFC5085A761Q31143315-34CEA530-DFDF-4F5C-9701-E6C8435BC625Q33439519-5BC30056-6361-4488-9AF4-2E3FDEFA243EQ33835928-36F86032-8F15-4C36-92C9-5593D1256E68Q34225916-88C9CF14-F838-48CC-BD9A-48B6F72D02CEQ34501562-E362DA8B-C018-47BF-AD8B-8D72AC9526B4Q35077393-73176FF4-D773-43CE-A466-1B0DECE21180Q35197045-AECEC426-BBE5-4456-A387-EC1EC4909BA3Q35962063-DD5A1638-D965-455D-B35A-A1E77385FFEAQ36107831-D5D95F0E-A9F3-4F78-9609-9FCA6E67573DQ36441522-888BDF65-7C17-479A-AF17-D2975FBE9CD5Q36846719-E54C5D6D-BEF8-481D-9AF8-D557F979B899Q37414261-12909C9D-ED59-40D4-87E9-F5DEA34E0326Q37417960-48A147AD-E296-47DC-A619-01DF89006182Q37628003-59B30B61-908A-48C1-AE71-DAE47E0FEDE4Q37716906-48AFD789-94F9-44FD-A401-B8C53214FBE1Q37718408-EAE0E4DA-E626-4D2C-AAE5-69D1BFD3A065Q38026611-AAA4ED34-1B13-4CB8-8F83-AF66F6B3F801Q38057689-09A0A58A-3027-4016-B773-8CC62C60FE98Q38084903-D2CFDB73-A246-410A-B651-19FB6525313DQ38109317-9C41D822-39CB-4AA8-A911-76F057603AFEQ38184928-19A3EA5B-C825-4750-A17C-6FD63C3EF2C5Q38270775-7192B806-7E46-4212-ABB4-79CBC97091D4Q38636990-F635A08C-27FA-4676-829A-1876F4BABF9FQ38645501-60AFC76B-F5F4-4B72-81CA-74AD5D366D87Q38820614-CC7C3B03-ECE0-4FFD-92C1-32741EE64871Q38896592-702FBE9A-895B-4DFE-9C6A-6DE1AB949634Q38902937-9C16018D-F791-44BE-ABEB-80DD532AE35EQ39181098-459D9B6D-838E-4F0E-83F7-103FAC18320EQ41180209-0EA3A93B-C6E3-44E8-AD95-C1D1A2145DDDQ41877061-693AFF29-1A9D-462B-8EB2-CAAF3D1AAF4BQ42321596-AA3DDFA8-E076-4AD0-9200-351FAA0663E6Q42365277-928A4508-8FE7-4C33-B1A1-49E6903750FCQ42679119-8450D53C-CB61-4D90-A4A6-96CA3F8FB318Q42966267-173B0CED-10ED-4464-A7B1-444152C635C3Q45937494-71946C13-17A0-4629-AA71-08C8AD5E52FAQ46037722-74CCFD35-21C1-49C0-BB26-BEC6D53556F5Q47224295-73787BDD-5AD8-4B94-91E7-79EEBB490CE8
P2860
FOXO3a represses VEGF expression through FOXM1-dependent and -independent mechanisms in breast cancer.
description
2011 nî lūn-bûn
@nan
2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
FOXO3a represses VEGF expressi ...... t mechanisms in breast cancer.
@ast
FOXO3a represses VEGF expressi ...... t mechanisms in breast cancer.
@en
type
label
FOXO3a represses VEGF expressi ...... t mechanisms in breast cancer.
@ast
FOXO3a represses VEGF expressi ...... t mechanisms in breast cancer.
@en
prefLabel
FOXO3a represses VEGF expressi ...... t mechanisms in breast cancer.
@ast
FOXO3a represses VEGF expressi ...... t mechanisms in breast cancer.
@en
P2093
P2860
P50
P356
P1433
P1476
FOXO3a represses VEGF expressi ...... nt mechanisms in breast cancer
@en
P2093
A K Zwolinska
C T Karadedou
J W H Tsang
K Y K Chan
M Petkovic
P2860
P2888
P304
P356
10.1038/ONC.2011.368
P407
P577
2011-08-22T00:00:00Z
P5875
P6179
1043673547